Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease

Stock Information for Serina Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Serina Therapeutics Inc.

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity
Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
Serina Therapeutics Provides Regulatory Update on SER-252 Program
Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors
Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease
Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.